20/20 Biolabs, Inc. Common Stock (AIDX) - Net Assets
Based on the latest financial reports, 20/20 Biolabs, Inc. Common Stock (AIDX) has net assets worth $108.46K USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.24 Million) and total liabilities ($3.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 20/20 Biolabs, Inc. Common Stock asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $108.46K |
| % of Total Assets | 3.35% |
| Annual Growth Rate | 8.75% |
| 5-Year Change | -54.73% |
| 10-Year Change | N/A |
| Growth Volatility | 212.53 |
20/20 Biolabs, Inc. Common Stock - Net Assets Trend (2016–2024)
This chart illustrates how 20/20 Biolabs, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore AIDX asset base for the complete picture of this company's asset base.
Annual Net Assets for 20/20 Biolabs, Inc. Common Stock (2016–2024)
The table below shows the annual net assets of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024. For live valuation and market cap data, see 20/20 Biolabs, Inc. Common Stock (AIDX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.53 Million | -64.22% |
| 2023-12-31 | $4.29 Million | -54.26% |
| 2022-12-31 | $9.37 Million | +36.06% |
| 2021-12-31 | $6.89 Million | +103.29% |
| 2020-12-31 | $3.39 Million | +57.69% |
| 2019-12-31 | $2.15 Million | -34.56% |
| 2018-12-31 | $3.28 Million | +620.03% |
| 2017-12-31 | $456.18K | -41.84% |
| 2016-12-31 | $784.36K | -- |
Equity Component Analysis
This analysis shows how different components contribute to 20/20 Biolabs, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1485878700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $48.23K | 3.14% |
| Other Components | $30.99 Million | 2020.21% |
| Total Equity | $1.53 Million | 100.00% |
20/20 Biolabs, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of 20/20 Biolabs, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
4DS Memory Ltd
AU:4DS
|
$16.04 Million |
|
Linius Technologies Ltd
AU:LNU
|
$16.06 Million |
|
Equus Total Return Closed Fund
NYSE:EQS
|
$16.06 Million |
|
Voltaic Strategic Resources Ltd
AU:VSR
|
$16.06 Million |
|
Climeon AB (publ)
ST:CLIME-B
|
$16.04 Million |
|
Rudrabhishek Enterprises Limited
NSE:REPL
|
$16.03 Million |
|
ZICOM Group Ltd
AU:ZGL
|
$16.02 Million |
|
Mega Polietilen Kopuk Sanayi ve Ticaret AS
IS:MEGAP
|
$16.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 20/20 Biolabs, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,287,492 to 1,534,216, a change of -2,753,276 (-64.2%).
- Net loss of 5,551,667 reduced equity.
- New share issuances of 293,333 increased equity.
- Other factors increased equity by 2,505,058.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.55 Million | -361.86% |
| Share Issuances | $293.33K | +19.12% |
| Other Changes | $2.51 Million | +163.28% |
| Total Change | $- | -64.22% |
Book Value vs Market Value Analysis
This analysis compares 20/20 Biolabs, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.85x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.09x to 4.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.17 | $1.55 | x |
| 2017-12-31 | $0.10 | $1.55 | x |
| 2018-12-31 | $0.70 | $1.55 | x |
| 2019-12-31 | $0.45 | $1.55 | x |
| 2020-12-31 | $0.72 | $1.55 | x |
| 2021-12-31 | $0.73 | $1.55 | x |
| 2022-12-31 | $0.99 | $1.55 | x |
| 2023-12-31 | $0.90 | $1.55 | x |
| 2024-12-31 | $0.32 | $1.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 20/20 Biolabs, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -361.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -316.81%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 2.36x
- Recent ROE (-361.86%) is below the historical average (-137.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -284.06% | -521.79% | 0.32x | 1.72x | $-2.31 Million |
| 2017 | -277.12% | -403.63% | 0.22x | 3.12x | $-1.31 Million |
| 2018 | -44.54% | -528.11% | 0.07x | 1.25x | $-1.79 Million |
| 2019 | -112.84% | -841.25% | 0.09x | 1.45x | $-2.64 Million |
| 2020 | -59.65% | -86.75% | 0.50x | 1.38x | $-2.36 Million |
| 2021 | 30.07% | 21.53% | 0.94x | 1.49x | $1.38 Million |
| 2022 | 23.33% | 19.77% | 0.91x | 1.30x | $1.25 Million |
| 2023 | -149.07% | -448.73% | 0.22x | 1.49x | $-6.82 Million |
| 2024 | -361.86% | -316.81% | 0.48x | 2.36x | $-5.71 Million |
Industry Comparison
This section compares 20/20 Biolabs, Inc. Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,702,872,176
- Average return on equity (ROE) among peers: -70.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $108.46K | -284.06% | 28.87x | $16.04 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About 20/20 Biolabs, Inc. Common Stock
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (… Read more